|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.590 |
Biomarker
|
disease |
BEFREE |
FOXM1-miR-21-5p-CDC25A and MYB/SOX4-miR-19b-3p-RBBP8 were identified as important feed-forward loops involved in the oncogenesis of T-ALL.
|
30646895 |
2019 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.590 |
GeneticVariation
|
disease |
BEFREE |
The protein is frequently overexpressed in human leukemias, breast cancers, and other solid tumors suggesting that it is a bona fide oncogene. c-MYB is often overexpressed by translocation in human tumors with t(6;7)(q23;q34) resulting in c-MYB-TCRβ in T cell ALL, t(X;6)(p11;q23) with c-MYB-GATA1 in acute basophilic leukemia, and t(6;9)(q22-23;p23-24) with c-MYB-NF1B in adenoid cystic carcinoma.
|
30599775 |
2019 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.590 |
Biomarker
|
disease |
CTD_human |
The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia.
|
28671688 |
2017 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.590 |
Biomarker
|
disease |
BEFREE |
Hereby, miR-193b-3p was identified as a novel bona fide tumor-suppressor miRNA that targets MYB during malignant T-cell transformation thereby offering an entry point for efficient MYB targeting-oriented therapies for human T-ALL.
|
25231743 |
2015 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.590 |
GeneticVariation
|
disease |
BEFREE |
Additional specific genomic events, were identified, namely FLT3 and CEBPA mutations in MDS/AML, and NOTCH1 mutations and MYB duplication in T-ALL.
|
26004809 |
2015 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.590 |
AlteredExpression
|
disease |
BEFREE |
T-ALL carrying NOTCH1 mutations had increased HES1 and MYB mRNA expression (HES1 9.2 ± 1.9 (mean ± SEM), MYB 8.7 ± 0.8 (mean ± SEM)) compared to T-ALL with wild-type NOTCH1 (HES1 1.8 ± 0.7, MYB 5.1 ± 1.2, P = 0.02 and 0.008, respectively).
|
24424791 |
2014 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.590 |
GeneticVariation
|
disease |
BEFREE |
In a subset of T-cell acute lymphoblastic leukemia (T-ALL) cases, we found that heterozygous somatic mutations are acquired that introduce binding motifs for the MYB transcription factor in a precise noncoding site, which creates a super-enhancer upstream of the TAL1 oncogene.
|
25394790 |
2014 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.590 |
Biomarker
|
disease |
BEFREE |
We conclude that Alu-mediated MYB tandem duplication occurs at low frequency during normal thymocyte development and is clonally selected during the molecular pathogenesis of human T-ALL.
|
18070937 |
2007 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.590 |
AlteredExpression
|
disease |
BEFREE |
Recent advances in the ability to assess DNA copy number have led to the discovery that the MYB transcription factor oncogene is tandemly duplicated in T-ALL.
|
17934490 |
2007 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.590 |
Biomarker
|
disease |
BEFREE |
Our results identify duplication of MYB as an oncogenic event and suggest that MYB could be a therapeutic target in human T-ALL.
|
17435759 |
2007 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.590 |
Biomarker
|
disease |
CTD_human |
Our results identify duplication of MYB as an oncogenic event and suggest that MYB could be a therapeutic target in human T-ALL.
|
17435759 |
2007 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.590 |
FusionGene
|
disease |
ORPHANET |
|
|
|
|
Adenoid Cystic Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Recent studies have indicated that a recurrent t(6;9)(q22-23;p23-24) chromosomal translocation in salivary adenoid cystic carcinoma (ACC) results in a MYB proto-oncogene transcription factor-nuclear factor I/B <i>(MYB-NFIB)</i> gene fusion, which has not previously been detected in any non-ACC carcinomas of the head and neck.
|
30854068 |
2019 |
|
Adenoid Cystic Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
There are no effective systemic therapies for adenoid cystic cancer (ACC) and lack of tumor lines and mouse models have hindered drug development.We aim to develop MYB-activated models for testing new therapeutic agents.
|
31606723 |
2019 |
|
Adenoid Cystic Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
For example, the MYB-NFIB fusion in adenoid cystic carcinoma is regulated by IGF1R through an autocrine loop, and IGF1R is a downstream target of the EWSR1-WT1 and PAX3-FKHR fusions in desmoplastic small round cell tumors and alveolar rhabdomyosarcoma, respectively.
|
31426421 |
2019 |
|
Adenoid Cystic Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Two prior studies showed t(6;9)/MYB-NFIB in tracheobronchial adenoid cystic carcinoma; however, only rare cases of MYBL1 rearrangement have been reported in this carcinoma.
|
31028361 |
2019 |
|
Adenoid Cystic Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
MYB-NFIB gene fusions identified in archival adenoid cystic carcinoma tissue employing NanoString analysis: an exploratory study.
|
31301736 |
2019 |
|
Adenoid Cystic Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry of protein expressions validated 4 upregulated genes (ODAM, HOXB13, MYB and SOX10) considered important and as potential biomarkers for spiradenomas and cylindromas.
|
31128548 |
2019 |
|
Adenoid Cystic Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
MYB-NFIB gene rearrangement occurs in 30-86% of salivary gland adenoid cystic carcinomas.
|
31189999 |
2019 |
|
Adenoid Cystic Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The protein is frequently overexpressed in human leukemias, breast cancers, and other solid tumors suggesting that it is a bona fide oncogene. c-MYB is often overexpressed by translocation in human tumors with t(6;7)(q23;q34) resulting in c-MYB-TCRβ in T cell ALL, t(X;6)(p11;q23) with c-MYB-GATA1 in acute basophilic leukemia, and t(6;9)(q22-23;p23-24) with c-MYB-NF1B in adenoid cystic carcinoma.
|
30599775 |
2019 |
|
Adenoid Cystic Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The presence of a translocation involving MYB and NFIB genes have been described in adenoid cystic carcinoma (AdCC) from different anatomical regions.
|
30269389 |
2019 |
|
Adenoid Cystic Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The aim of this meta-analysis is to evaluate myeloblastosis (MYB) as a prognostic marker for patients with adenoid cystic carcinoma (ACC) with respect to MYB gene fusion, MYB protein expression, and tumor sites.
|
30759319 |
2019 |
|
Adenoid Cystic Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MYB-NFIB fusion was detected in 57/85 (67.1%), MYBL1-NFIB fusion in 12/85 (14.1%), MYB-X fusion in 4/85 (4.7%), MYBL1-X in 4/85 (4.7%), and NFIB-X in 2/85 (2.4%) of AdCC cases.
|
29619555 |
2018 |
|
Adenoid Cystic Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MYB rearrangement and immunohistochemical expression in adenomyoepithelioma of the breast: a comparison with adenoid cystic carcinoma.
|
30003572 |
2018 |
|
Adenoid Cystic Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MYB and MYBL1 in adenoid cystic carcinoma: diversity in the mode of genomic rearrangement and transcripts.
|
29410490 |
2018 |